PDF Return
C. 77
To: Board of Supervisors
From: Anna Roth, Health Services Director
Date: August  6, 2019
The Seal of Contra Costa County, CA
Contra
Costa
County
Subject: Purchase Order with Polymedco, Inc

APPROVE OTHER
RECOMMENDATION OF CNTY ADMINISTRATOR RECOMMENDATION OF BOARD COMMITTEE

Action of Board On:   08/06/2019
APPROVED AS RECOMMENDED OTHER
Clerks Notes:

VOTE OF SUPERVISORS

AYE:
John Gioia, District I Supervisor
Candace Andersen, District II Supervisor
Diane Burgis, District III Supervisor
Karen Mitchoff, District IV Supervisor
Federal D. Glover, District V Supervisor
Contact: Jaspreet Benepal, 925-370-5101
cc: Marcy Wilhelm     Margaret Harris    
I hereby certify that this is a true and correct copy of an action taken and entered on the minutes of the Board of Supervisors on the date shown.
ATTESTED:     August  6, 2019
David Twa,
 
BY: , Deputy

 

RECOMMENDATION(S):

APPROVE and AUTHORIZE the Purchasing Agent to execute, on behalf of the Health Services Director, a Purchase Order with Polymedco, Inc., in an amount not to exceed $600,000 for the purchase of reagents and supplies to perform immunochemical fecal occult blood testing for the Clinical Laboratory at Contra Costa Regional Medical Center (CCRMC), for the period of October 1, 2019 to September 30, 2022.

FISCAL IMPACT:

100% funding is included in the Hospital Enterprise Fund I budget.













BACKGROUND:

Polymedco, Inc.’s OC-Auto Micro 80 Analyzer with FOBT-CHECK OC reagents is an automated immunochemical fecal occult blood testing system that detects human red cells only with no interferences from red meat, turnips, melons, aspirin, anti-inflammatory drugs and vitamin C. This improvement directs many more of the “right” patients to colonoscopy leading to the earlier detection of polyps and colorectal cancer. The increased sensitivity and specifics of this test over the current method is expected to improve detection of early stage colon cancer, which currently is the third most common cancer and the second leading cause of cancer deaths in the U.S. at 30%. The increased specificity results in fewer false positives, allowing the correct identification of those patients who need expensive colonoscopy procedures. Replacing the sigmoidoscopy and colonoscopy with this lab test for cancer screening will significantly reduce the overall healthcare cost to the organization.  

CONSEQUENCE OF NEGATIVE ACTION:

If this Purchase Order is not approved, then the CCRMC Clinical Laboratory will not be able to perform patient testing for colorectal cancer.

AgendaQuick©2005 - 2024 Destiny Software Inc., All Rights Reserved